cannabigerol + tetrahydrocannabinol

**Cannabigerol + tetrahydrocannabinol** is a combination of two naturally occurring cannabinoids found in *Cannabis sativa*: cannabigerol (CBG) and delta-9-tetrahydrocannabinol (THC). THC is known for its psychoactive activity as a partial agonist at the cannabinoid receptor type 1 (CB1), as well as effects at CB2, responsible for cytotoxicity and apoptosis in various cell types, including tumor cells[1][2]. CBG is a non-psychoactive cannabinoid that acts as a weak agonist at CB1 and a partial agonist at CB2, and is also active at other receptors such as TRPV1/2/3/4, TRPA1, TRPM8, PPARγ, α2-adrenoceptor, and 5-HT1A, modulating various physiological and pathophysiological pathways including inflammation, apoptosis, and metabolic effects[2][3]. While both THC and CBG exhibit cytostatic, pro-apoptotic, anti-invasive, and immunomodulatory effects relevant in oncology, particularly glioblastoma and other cancer indications, CBG is non-intoxicating and may possess a more favorable side effect profile. Most research to date examines potential antineoplastic, analgesic, anti-inflammatory, and metabolic effects[1][2][3][4].

Other names

CBG + THC